| Nov 17 |
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 14 |
Fortress Biotech GAAP EPS of -$0.76 misses by $0.17, revenue of $14.62M
|
| Nov 14 |
Fortress Biotech: Q3 Earnings Snapshot
|
| Nov 14 |
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 14 |
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 12 |
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
|
| Nov 12 |
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 12 |
Mustang Bio Receives Positive Listing Determination from Nasdaq
|
| Nov 7 |
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
|
| Nov 4 |
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
|
